TissueGen is a developer of next generation drug delivery technologies. TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life changing treatment modalities for patients and their caregivers, treating both acute and chronic conditions.

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Development of CAR-T cell based cancer therapies T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

96 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We incubate, fund, and launch new companies that use programmed biology to shape the human future. Ferment is a venture studio building new companies that rapidly translate biology into products that solve targeted problems across industrial and consumer markets including food & nutrition, industrials & waste, materials, consumer health and more. synbio, synthetic biology, biotech, programmed biology, venture studio, company creation studio, incubator, venture capital, biotechnology, industrial biotechnology, and consumer biotechnology

73 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Restoring life after organ failure. eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant. Genome Engineering

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biomade Peptides We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A WuXi Advanced Therapies company, based in Oxford, UK. OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers around the world with the technologies, automation platforms and service solutions they need to come first in the race to deliver ground-breaking therapeutics. OXGENETM is headquartered in Oxford, UK. For additional information, please visit our website. PRODUCTS: Largest collection of standardised plasmids on the market and SERVICES: DNA Services, Protein Production Services, Virus Services, Cell Line Development Services.

113 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Fast, integrated structural biology for drug discovery — MX, cryo-EM and biophysics. ALPX is an innovative structural biology company spun out of EMBL Grenoble, supporting pharma and biotech partners in structure-based drug discovery. We provide automated MX, cryo-EM and biophysics services to help teams move faster from protein to structure to decision. Our platforms can be tailored to each project and, when useful, run in parallel to identify the best path with speed and confidence. Our expertise covers small molecules, biologics, membrane proteins and targeted protein degradation complexes, from high-resolution structure determination to mechanistic interpretation. Speed, flexibility and transparency define …

85 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Advanced Biomaterials for Regenerative Medicine Tensive is a biomedical company developing advanced biomaterials for regenerative medicine applications, with a current focus on reconstructive surgery after breast cancer.

77 similar entities Type: Startup Activities: deeptech healthtech Technologies: New Materials Synthetic Biology

Developing best-in-class NNMT inhibitors with a dual therapeutic effect to benefit patients with metabolic syndrome Cantoni Therapeutics is a biopharmaceutical spinout company from the University of Leiden (NL) developing best-in-class inhibitors of a single enzyme with a dual therapeutic effect to benefit patients with metabolic syndrome.

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pan Cancer T is a biotech company developing T cell receptor (TCR) T-cell therapy for solid tumours Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Inscripta merged with Manus in April 2025 to establish a unique end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products. By combining Inscripta’s advanced whole-genome engineering technologies with Manus’ proven cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged company – Manus – is uniquely positioned to deliver commercial momentum and scaled profitability in next-generation industrial biotechnology.

61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Innovation focused private biotech dedicated to delivering next-generation multispecific antibody therapeutics. F-star is a private biotech, based in Cambridge UK, focused on using our world-leading, innovative bispecific antibody technology that is clinically validated, patent protected and designed to create therapeutics that help more people with cancer and other serious diseases live longer with improved lives. bispecific antibodies, immuno-oncology, Immmunotherapy, oncology, cancer, tetravalent bispecifics, cancer research, biotech, immunology, CNS, and autoimmunity

101 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to produce non-transgenic, regulatory free, sustainable, consumer oriented genome edited plant products. PLANTeDIT is the first biotech company dedicated to use patented next generation genome editing tools CRISPR/Cas9 RNPs® from our key collaborator Toolgen (http://toolgen.com/?lang=en) with our transformation technology for efficient direct delivery and swift regeneration of genome edited plants. Our mission is also to revolutionize plant transformation technology with our innovative, universal, cost effective, swift transformation system applicable to broad a range of crop species for direct delivery of genome editing tools. Further, PLANTeDIT aims to develop highly pure mammalian protein and human drugs at cost …

57 similar entities Type: Startup Activities: biotech deeptech agritech Technologies: Synthetic Biology

Biologics of a New Generation to Treat Allergy ANGANY is a private, early clinical stage pharmaceutical company, based in Lévis, QC, Canada. ANGANY has tackled the specific challenges of allergy to invent a novel class of biologics. ANGANY has developed an exclusive therapeutic platform based on synthetic biology: the eBioparticle TM, a self-adjuvant vector bringing novel features of safety and potent immunomodulation to thwart allergy.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

DNA Synthesis Uncompromised Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis (or FESTM), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering Hope MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering smarter gene modulation for breakthrough cell and gene therapies Antion Biosciences is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies tools. Antion has developed a proprietary gene engineering technology with unmatched versatility to overcome key challenges facing cell and gene therapy. Our patent-protected technologies are versatile, highly effective and broadly applicable to various therapeutic areas. We actively explore collaborations and partnering opportunities to out-license our proprietary technologies. Gene and Cell therapies and Genetic engineering

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

344 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

264 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

298 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FoRx Therapeutics is developing therapeutics that exploit the presence of DNA replication stress in human cancers FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Memo Therapeutics AG, an Ipsen company, is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections.

215 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Tiziana Life Sciences LTD is a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company Tiziana Life Sciences LTD is a biotechnology company focused on transformational technology enabling alternative routes for immunotherapy.

59 similar entities Type: Startup Activities: deeptech biotech

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

512 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

New view for cancer therapeutics Sirius NeoSight is an innovative technological breakthrough company which aims to become a key player in the detection of subclinical neo-cancers, relapses and therapeutic monitoring of patients, thus offering doctors a new perspective on the therapeutic effectiveness implemented. Sirius NeoSight uses breakthrough patented technology from a consortium of academic laboratories with expertise in the field.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

81 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

359 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Vetbiolix develops innovative products for the treatment and prevention of chronic diseases affecting the chi Vetbiolix develops innovative products for the treatment and prevention of chronic diseases affecting dogs and cats.

110 similar entities Type: Startup Activities: pettech deeptech biotech healthtech Technologies: Synthetic Biology

e-Zyvec services by Polyplus provide tailor-made plasmids that really fit your needs! e-Zyvec is a French Biotech Start-up founded in 2016 as a spin-off of the University of Lille 1. We are providing unique solutions in molecular biology to academical or industrial scientists working on research project with genetic engineering applications. Using our proprietary DNA assembly technology and our in-house developped web application, we can design and produce fully customized gene expression vectors, fitting exactly the requirements of your project. Getting vectors with e-zyvec is fast, accurate and unrestrictive. Molecular Biology and Genetic Enginnering

59 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

138 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

227 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nano Drug Solutions Revolutionizing neuropathy treatment Development of innovative nanomedicines targeting neuropathies, with a particular focus on hereditary neuropathies such as Charcot-Marie-Tooth disease Biothechnology

150 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Turn cancer immunotherapies active in most patient Stimunity is a startup company from Institut Curie which develops bio-pharmaceuticals to treat patients that do not respond to immunotherapy in cancer.

60 similar entities Type: Startup Activities: biotech deeptech

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Disruptive Solutions, Healthier Futures FOSCA BioTech is developing disruptive technologies to simultaneously remove multiple cancer-related molecules, transforming cancer treatment approaches with unprecedented precision.

60 similar entities Type: Startup Activities: deeptech biotech

Theraonco enhance efficacity of wide range of payload agents and reduces their side effects Thanks to the specific assimilation of patented modified sugars equipped with chemical hooks by the tumoral cells, we can concentrate locally any type of payload through a reaction based on « click » chemistry (Nobel Prize, 2022) with carrier containing payload that “click” on the hooks. We want to use this approach to fight against cancer.

95 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nanoparticle-Based Radiopharmaceuticals for Targeted Radiation Delivery to Cancer Cells aKen Medical is a biotechnology company that encapsulates highly potent radioactive materials within stable nanoparticles serving as "guided missiles" that deliver targeted radiation straight to tumors while protecting healthy tissue. Our universal nanoparticle platform is designed to address a wide range of cancers, enabling real-time monitoring and advancing a theranostic approach that paves the way for precision medicine. Radiopharmaceuticals, Targeted therapy, Theranostics, Radiation Therapy, Alphatherapy, Nanotechnology, Cancer Therapy, Biotechnology, Radiotherapy, and Precision Medecine

127 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to develop the medicines of the future VeonGen Therapeutics (formerly known as ViGeneron) was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At VeonGen Therapeutics we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. VeonGen Therapeutics will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our VeonGen Therapeutics technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Optimizing your gene transfer workflows with GEG Tech technologies GEG Tech is a French Deeptech company specializing in genetic engineering, developing innovative technologies for advanced therapies, including gene therapies, vaccines, cancer immunotherapies and dermatology. GEG Tech designs DNA vectors and has invented a new generation of biological mRNA vectors that are far more efficient than chemical nanoparticles and safer than viral vectors. With 12 years of experience in genetic engineering, the company operates as a studio-lab, serving clients primarily in the United States and Europe. GEG Tech’s scientific team originates from the CNRS, and its laboratory is based on the …

78 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech

61 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Follow us at Shionogi Inc. for news about our rare disease research programs https://www.linkedin.com/company/shionogi-inc-/ drug discovery, PDE4D, PDE4B, Fragile X, CTE, Rubinstein-Taybi, traumatic brain injury, Clinical Trials, Fragile X syndrome, Cognition, BPN14770, and Memory Loss

364 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Wholly Owned Subsidiary of Eli Lilly and Company Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies for oncogene-driven cancers Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers. Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Repair the liver without graft GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative science to improve the health of patients To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results …

130 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Wholly Owned Subsidiary of Eli Lilly and Company Orna Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Safer, more effective ADCs and protein-drug-conjugates with GoldenSiteTM technology VALANX has built GoldenSite, a site-specific conjugation platform that places ADC payloads in structurally shielded positions on the antibody, delivering significantly reduced off-target interaction while preserving and enhancing efficacy. Using GoldenSite, we are developing a LIV-1 targeting, differentiated ADC intended to treat metastatic triple-negative-breast cancer. Bioconjugation, Site-specific conjugation, PEGylation, Biotechnology, Research and Development, ADCs, Novel format conjugates, Radioconjugates, Next generation bioconjugates , and Site-agnostic conjugation

87 similar entities Tags: H2020 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Development of innovative drugs with curative potential in Immunology and Cancerology. Beta Innov SAS is an innovative pharmaceutical Research and Development company, created in March 2009 by patient families. Beta Innov aims to achieve a major therapeutic leap in the treatment of autoimmune diseases and Glioblastoma by using a physiological (Immunology) or metabolic (Glioblastoma) approach, avoiding the costs of gene therapies and the adverse effects of antibody therapies.

59 similar entities Type: Startup Activities: biotech manufacturing deeptech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

114 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcells

246 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making better ADCs Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications. Valink is a platform therapeutics company focussing on the discovery of bsADCs based out of Cambridge, MA and London, UK. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $20M total capital raised.

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A versatile immunotherapy for personalized cancer medicine Inovactis is developing an innovative treatment against cancer on the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. immunotherapy and personalized medicine

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

519 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Personalized Transplants VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.

65 similar entities Type: SMB Activities: biotech deeptech Technologies: SaaS

Genenta Science (Nasdaq: GNTA), which will be renamed as Saentra Forge (Nasdaq: SAEN) About: Genenta Science (Nasdaq: GNTA), which will be renamed as Saentra Forge (Nasdaq: SAEN, pending effectiveness), will be a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity. Defence, Cybersecurity, Aerospace, and National Security

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

60 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

113 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

297 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Providing cancer patients with a longer and better life Atonco is a clinical-stage radiopharmaceutical company developing innovative radiopharmaceutical products using astatine-211, an alpha-emitting radionuclide for the treatment of cancer. Atonco, founded in 2019, built with an experienced and passionate team, has exclusive global licenses for the use of an innovative proprietary antibody and radiolabeling technology.

68 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective …

61 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

72 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell Tree Analytics, somatic mutation tracking, clonal structure quantification, check out our Cell Tree Rings study here https://www.biorxiv.org/content/10.1101/2022.12.14.520419v1 mass spec proteomics, aging

69 similar entities Type: Startup Activities: deeptech greentech Technologies: Synthetic Biology

Procavea Biotech is on a mission to solve the problem of delivering RNA-based drugs to non-liver tissues. At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body. Protein Engineering and RNA Delivery

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The cloud lab for protein designers Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.

74 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

146 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Reversing Neurodegeneration - Restoring Life GeneCode is developing small-molecule drugs that bind and activate GDNF (Glial cell line-Derived Neurotrophic Factor) receptors for the treatment of Parkinson’s disease (PD) and other neurodegenerative conditions.

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing healthcare through innovative adenosine receptor-based drugs Palobiofarma S.L. is a Spanish biopharmaceutical company dedicated to discovering and developing innovative drugs based on the modulation of adenosine receptors.

107 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

206 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Enabling the next generation of medicines Lentivirus is challenging to manufacture. Unwanted transgene expression and viral genome instability are two common and critical issues. Lentitek can help you solve these challenges through a combination of expert design services and the incorporation of our unique manufacturing technology, which effectively eliminates unwanted transgene expression by stabilising the vector genome during the manufacturing process. Our approach enables you to optimise vector performance, enhance quality and safety, and minimise potentially hazardous off-target effects.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineered Immunity Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are …

96 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nanovery - experts in nucleic acid quantification using nanorobots. We have created a proprietary Nucleic Acid Nanorobotics (NANs) platform that simplifies molecular testing and quantification for RNA therapeutics and biomarkers.

77 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

514 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Altamira is developing peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. Altamira Therapeutics is developing and supplying peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. This versatile technology is suited for delivering different nucleic acid modalities: OligoPhoreTM for small RNAs (siRNA/ASO), SemaPhoreTM for mRNA, CycloPhoreTM for circRNA and GenePhoreTM for DNA. xPhoreTM is licensed to pharma and biotech companies for use with their proprietary nucleic acid molecules. The Company currently has two proprietary siRNA programs using OligoPhoreTM in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology